newsfilter
← Latest News
PR Newswire·

PolarityTE Announces Submission of Complete Response to FDA's Clinical Hold Correspondence for SkinTE® Investigational New Drug Application

SALT LAKE CITY, Dec. 20, 2021 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that it has submitted its complete response to the U.S. Food and Drug Administr